Tag: bol pharma

CALGARY, AB, Oct. 4, 2022 /CNW/ – Decibel Cannabis Company Inc. (the “Company” or “Decibel”) (TSX-V: DB) (OTCQB: DBCCF), a premium cannabis producer, is pleased to announce it has secured an on-going supply agreement with Breath of Life International Ltd. (“Breath of Life” or “BOL”) to launch Decibel’s Qwest brand and cannabis products in Israel. The supply agreement is for $4.8 million of premium cannabis product, with the first shipment expected in the fourth quarter. Read...

St. Paul, MN — Kindeva Drug Delivery (Kindeva) and Breath of Life International (BOL Pharma or BOL) have agreed to the use of low GWP propellants in multiple inhaled cannabinoid products. Kindeva will develop novel formulations of BOL Pharma’s cannabinoid-based drug products delivered by Kindeva’s pressurized metered-dose inhaler (pMDI) technology using the next generation of low GWP propellants. Subject to all required regulatory approvals, the products under development are targeted to treat chronic neuropathic pain. If successful, this early-stage activity could lead to the long-term commercial supply of regulated inhaled cannabinoid products using low GWP propellants, leveraging Kindeva’s commercial manufacturing capabilities and BOL’s accumulated know-how and innovation in the field of medical cannabis. Read...

Part of larger supply agreement with BOL Pharma to serve rapidly growing number of medical cannabis patients in Israel Read...

Kindeva Drug Delivery (Kindeva) and Breath of Life International (BOL Pharma or BOL) have signed an agreement to study the feasibility of multiple inhaled cannabinoid products. Under the agreement, Kindeva will develop novel formulations of BOL Pharma’s cannabinoid-based drug products delivered by Kindeva’s metered-dose inhaler (MDI) technology. Subject to all required regulatory approvals, the products under development could go on to treat a range of central nervous system diseases, including autism spectrum disorder, epilepsy, and general severe pain and anxiety experienced as part of conditions such as palliative care and diabetic neuropathy. If successful, this early-stage activity could lead to the long-term commercial supply of regulated inhaled cannabinoid products, leveraging Kindeva’s commercial manufacturing capabilities and BOL’s accumulated know-how and innovation in the field of medical cannabis. Read...

Panaxia became the first publicly held medical cannabis company in Israel to receive the requested standard, and the second Israeli company overall, after BOL Pharma received the coveted standard in January, and even made its firstcommercial export to the U.K. Read...